Brief: Ryvu Therapeutics Revises Portfolio Of Research Projects

Ryvu Therapeutics SA

21/10/2020 08:08

Oct 21 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * REVISES PORTFOLIO OF RESEARCH PROJECTS
    * SAYS DECIDED TO COMPLETE PROJECT TO DEVELOP A DUAL
ADENOSINE
RECEPTOR ANTAGONIST (A2A / A2B) AND THE SYNTHETIC LETHALITY
PROJECT (SMARCA2)
    * SAYS THANKS TO REVISION OF PORTFOLIO COMPANY WILL BE ABLE
TO
CONCENTRATE ON  SEL120 PROJECT, WHICH IS IN THE CLINICAL
RESEARCH STAGE AND OTHER PRE-CLINICAL PROJECTS
    * HAS STARTED WORK ON PROTEIN TARGETS

Source text for Eikon:  ID:nEMbSdc6Ba 
Further company coverage:  RVU.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))